U.S. Pharmacist



Erosion of Branded Dyslipidemia Drug Sales Likely

By Staff


US Pharm. 2009;34(9):34-36. 

According to a report from Decision Resources, a research and advisory firm that specializes in pharmaceutical and health care issues, over the next 10 years sales of branded drugs in the dyslipidemia market will erode by some $4 billion worldwide as generic versions are introduced, most notably in the area of key statins such as atorvastatin and rosuvastatin.

Although generic erosion will certainly take place, the report also finds that opportunity exists in the development of agents that modify lipid parameters for the growing number of patients with mixed dyslipidemia, which is characterized by elevated LDL cholesterol and triglyceride levels combined with decreased levels of HDL cholesterol.

"We forecast that approximately 6% of patients who are currently prescribed individually formulated statins will be prescribed fixed-dosed combinations containing a statin by 2018," said Decision Resources Analyst Alana Lessi.

U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Copyright © 2000 - 2016 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.